Commentary

Influenza vaccine does not produce myopathy in patients taking statins


 

References

To the editor:

Influenza is an acute febrile illness caused by infection with influenza virus A&B. Clinical manifestations are fever, myalgia, and cough. Myositis (symptomatic or laboratory confirmed) and rhabdomyolysis have also been reported.1 Influenza vaccine is recommended for populations at increased risk for developing complications.

Myopathic syndromes are one of the major adverse effects of HMG-CoA reductase inhibitors (“statins”). Only 1 case of rhabdomyolysis after influenza vaccine in a patient using statins has been reported.2 We attempted to determine if influenza vaccine given to patients treated with statins causes asymptomatic or symptomatic myopathy.

Our study was conducted in outpatient rural clinics of Clalit Health Services in north Israel, during October 2001. Patients were eligible if they were at least 50 years of age and had received an influenza vaccine. A 5-mL blood sample for creatine phosphokinase (CPK) and aldolase levels was obtained before and 5 to 7 days after vaccination. Clinical and demographic data as well as reactions after the vaccination were recorded. We studied 98 patients: 52 who received statins and 46 controls. Their mean age was 69.7 years (range, 50–91 years). Clinical and demographic characteristics were similar in both groups.

Local reactions (rubor, pain, mild swelling) were reported in 20 patients (20.2%): 7 in the statin group and 13 in the control group (P = NS). These reactions improved after a few days without treatment. Only 2 patients (2%) (1 in each group) had myalgia. CPK and aldolase levels were measured before and after influenza vaccination for the entire study population and were analyzed separately by sex (because of sex differences in total muscle mass and normal ranges). CPK levels increased slightly, but not significantly, after influenza vaccination in both groups of female patients, and in male patients only in the control group. The only significant change observed was an increase in aldolase levels after influenza vaccine in female control subjects (P = .013). All CPK and aldolase values before and after vaccination were within normal ranges.

Thus, we found no indication in this pilot study that influenza vaccination causes clinical or laboratory evidence of myopathy in patients taking statins.

Chazan Bibiana, MD
Ha’Emek Medical Center, Afula, Israel
Ben-Gurion University, Beer-Sheba, Israel
E-mail: chazan_b@clalit.org.il

Weiss Rachel, MD; and Tabenkin Hava, MD
Ben-Gurion University, Beer-Sheba, Israel

Mines Miguel, MsC
Ha’Emek Medical Center, Afula, Israel
Raz Raul, MD Ha’Emek Medical Center, Afula, Israel
Technion School of Medicine, Haifa, Israel

Recommended Reading

Improving influenza vaccination rates in the elderly
MDedge Family Medicine
Childhood Vaccinations
MDedge Family Medicine
Does a multivalent pneumococcal vaccine given to infants prevent otitis media?
MDedge Family Medicine
Diagnosing Influenza: The Value of Clinical Clues and Laboratory Tests
MDedge Family Medicine
Effects [FET1] of Influenza Vaccination of Health Care Workers on Mortality of Elderly People in Long-Term Care: A Randomized Controlled Trial
MDedge Family Medicine
Reconnoitering the Antivaccination Web Sites: News From the Front
MDedge Family Medicine
Time for Changes in Immunization
MDedge Family Medicine
Practices of Family Physicians and Pediatricians in Administering Poliovirus Vaccine
MDedge Family Medicine
Is oral oseltamivir safe and effective for the prevention of influenza and its complications in frail elderly long-term care residents who have received influenza vaccine?
MDedge Family Medicine
A Comprehensive Investigation of Barriers to Adult Immunization A Methods Paper
MDedge Family Medicine